Clinical Profiles and Survival Outcomes in Patients with De Novo Metastatic Non-small Cell Lung Carcinoma – A Real World Analysis from a Tertiary Cancer Centre

Background: Lung cancer remains the most common cancer worldwide, accounting for 11.4% of all cancers and 18% of all cancer deaths. The age-adjusted incidence of lung cancer in India shows a rising trend since 1980s (NCDIR). Understanding the clinico-epidemiological profile is crucial to assess the impact of prevention and treatment strategies. Methods: This study retrospectively analysed patients (>18 years) with de novo metastatic non-small cell lung carcinoma (NSCLC) treated at our centre between January 2020 to December 2022. Data on demography, disease profile, treatment and outcomes were analysed, and survival analysis done using Kaplan-Meier and Cox regression models. Results: Total 358 patients were analysed. Mean age at diagnosis was 52 (range 24-81) years with male preponderance (77%) and 55% had history of tobacco use. Adenocarcinoma was the predominant histology (79%). Common driver mutations seen were EGFR mutation (25%; MC are EGFR exon 19 deletion and L858R point mutation), ALK gene rearrangement (4%), and ROS1 mutation (